

11. AN AMENDMENT TO BE OFFERED BY REPRESENTATIVE
LYNCH OF MASSACHUSETTS, OR HIS DESIGNEE,
DEBATABLE FOR 10 MINUTES:

9

Revised

**AMENDMENT TO H.R. 2829, AS REPORTED
OFFERED BY MR. LYNCH OF MASSACHUSETTS**

At the end of the bill, add the following (and make such conforming changes as may be necessary to the table of contents):

1 **SEC. 20. STUDY ON PRESCRIPTION DRUGS ASSOCIATED**
2 **WITH IATROGENIC ADDICTION.**

3 (a) IN GENERAL.—The Director of the Office of Na-
4 tional Drug Control Policy shall request the Institute of
5 Medicine of the National Academy of Sciences to enter
6 into an agreement under which the Institute agrees to con-
7 duct a study examining certain aspects of prescription
8 drugs associated with iatrogenic addiction, including
9 oxycodone hydrochloride controlled-release tablets.

10 (b) REQUIREMENTS.—The study conducted pursuant
11 to this section shall evaluate—

12 (1) the rate and impact of iatrogenic addiction
13 associated with the use of prescription drugs de-
14 scribed in subsection (a); and

15 (2) the relative addictiveness of prescription
16 drugs described in subsection (a) when compared
17 with other opioids and other substances included in
18 schedule I or II of the schedules of controlled sub-



1 stances established by section 202 of the Controlled
2 Substances Act (21 U.S.C. 812).

3 (c) REPORT.—The Director of the Office of National
4 Drug Control Policy shall ensure that the agreement
5 under subsection (a) provides for the submission of a re-
6 port to the Congress, not later than one year after the
7 date of the enactment of this Act, on the results of the
8 study conducted pursuant to this section.

